August 4, 2025

Integrated Genomic Profiling Identifies Predictive Biomarkers for Neoadjuvant Therapy Response in Chinese Breast Cancers

View Full Paper

Ask AI

Bookmark

Authors

XYXiaohan YingCornell University KZKunyu ZhangFudan University Shanghai Cancer Center XZXiuzhi ZhuFudan University Shanghai Cancer Center

Discussion

Member takes

Implication

Integrated genomic profiling identifies predictive biomarkers for neoadjuvant therapy response in breast cancer, suggesting potential for personalized treatment strategies.

Key Points

Neoadjuvant therapy is a standard treatment for advanced breast cancer, but predictive biomarkers are needed.
Significant genomic alterations, such as PIK3CA mutations, have been linked to therapy resistance in specific breast cancer subtypes.
A large cohort of 1,161 breast cancer patients was analyzed to identify predictors of neoadjuvant therapy efficacy.
Machine learning models successfully predicted neoadjuvant therapy response with AUCs of 0.82 in training and 0.81 in validation.

Cite This Study

Ying et al. (2025) studied this question.

synapsesocial.com/papers/689a0f86e6551bb0af8d0b20 https://doi.org/10.21203/rs.3.rs-7055446/v1

View Full Paper

Ask AI

Bookmark

Implication

Integrated genomic profiling identifies predictive biomarkers for neoadjuvant therapy response in breast cancer, suggesting potential for personalized treatment strategies.

Integrated Genomic Profiling Identifies Predictive Biomarkers for Neoadjuvant Therapy Response in Chinese Breast Cancers

Discussion

Member takes

Implication

Key Points

Cite This Study

Integrated Genomic Profiling Identifies Predictive Biomarkers for Neoadjuvant Therapy Response in Chinese Breast Cancers

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider